• Je něco špatně v tomto záznamu ?

Superficial acral fibromyxoma: clinicopathological, immunohistochemical, and molecular study of 11 cases highlighting frequent Rb1 loss/deletions

A. Agaimy, M. Michal, J. Giedl, L. Hadravsky, M. Michal,

. 2017 ; 60 (-) : 192-198. [pub] 20161104

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031303

Superficial acral fibromyxoma (SAF) is an uncommon benign dermal mesenchymal lesion of adults with predilection for acral sites, in particular the nail region. To date, less than 300 cases have been reported. SAFs consistently express CD34, but other diagnostic markers or specific genetic alterations have not been established yet. We describe 11 SAFs occurring in 7 men and 4 women aged 37 to 86years (median, 48 years). Mean size was 6mm (range, 4-20mm). Affected sites were fingers (n=5), toes (n=3), heel (n=1), calf (n=1), and unspecified digit (n=1). None of 10 patients with available follow-up (2-60months; median, 24months) developed recurrence. Histology showed relatively hypocellular vaguely lobulated nodules composed of bland-looking spindled or stellate fibroblast-like cells arranged into storiform or loose fascicles within a variably myxoid, fibromyxoid, or collagenous vascularized stroma. Immunohistochemistry showed expression of CD34 (9/10) and focal weak reactivity for epithelial membrane antigen (2/11). None of the lesions expressed protein S100 (0/11), MUC4 (0/11), or STAT6 (0/11). Loss of Rb1 immunoexpression was observed in 9 (90%) of 10 cases. All 7 cases with successful RB1 fluorescence in situ hybridization testing showed RB1 gene deletions, which was variably associated with co-loss of the corresponding 13q12 signal (monosomy at the 13q region). To our knowledge, this is the first study investigating the expression status of the tumor suppressor Rb1 in SAF by immunohistochemistry and fluorescence in situ hybridization. Our results showed frequent Rb1 deficiency as a possible driver molecular event in SAF (seen in 90% of cases) indicating relationship of SAF to the RB1-deleted tumor family.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031303
003      
CZ-PrNML
005      
20171025122940.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.humpath.2016.10.016 $2 doi
035    __
$a (PubMed)27825811
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Agaimy, Abbas $u Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital, 91054 Erlangen, Germany. Electronic address: abbas.agaimy@uk-erlangen.de. $7 gn_A_00002061
245    10
$a Superficial acral fibromyxoma: clinicopathological, immunohistochemical, and molecular study of 11 cases highlighting frequent Rb1 loss/deletions / $c A. Agaimy, M. Michal, J. Giedl, L. Hadravsky, M. Michal,
520    9_
$a Superficial acral fibromyxoma (SAF) is an uncommon benign dermal mesenchymal lesion of adults with predilection for acral sites, in particular the nail region. To date, less than 300 cases have been reported. SAFs consistently express CD34, but other diagnostic markers or specific genetic alterations have not been established yet. We describe 11 SAFs occurring in 7 men and 4 women aged 37 to 86years (median, 48 years). Mean size was 6mm (range, 4-20mm). Affected sites were fingers (n=5), toes (n=3), heel (n=1), calf (n=1), and unspecified digit (n=1). None of 10 patients with available follow-up (2-60months; median, 24months) developed recurrence. Histology showed relatively hypocellular vaguely lobulated nodules composed of bland-looking spindled or stellate fibroblast-like cells arranged into storiform or loose fascicles within a variably myxoid, fibromyxoid, or collagenous vascularized stroma. Immunohistochemistry showed expression of CD34 (9/10) and focal weak reactivity for epithelial membrane antigen (2/11). None of the lesions expressed protein S100 (0/11), MUC4 (0/11), or STAT6 (0/11). Loss of Rb1 immunoexpression was observed in 9 (90%) of 10 cases. All 7 cases with successful RB1 fluorescence in situ hybridization testing showed RB1 gene deletions, which was variably associated with co-loss of the corresponding 13q12 signal (monosomy at the 13q region). To our knowledge, this is the first study investigating the expression status of the tumor suppressor Rb1 in SAF by immunohistochemistry and fluorescence in situ hybridization. Our results showed frequent Rb1 deficiency as a possible driver molecular event in SAF (seen in 90% of cases) indicating relationship of SAF to the RB1-deleted tumor family.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x analýza $x genetika $7 D014408
650    _2
$a biopsie $7 D001706
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibrom $x chemie $x diagnóza $x genetika $x patologie $x chirurgie $7 D005350
650    12
$a delece genu $7 D017353
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    12
$a imunohistochemie $7 D007150
650    12
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fenotyp $7 D010641
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a vazebné proteiny retinoblastomu $x analýza $x genetika $7 D056286
650    _2
$a nádory kůže $x chemie $x diagnóza $x genetika $x patologie $x chirurgie $7 D012878
650    _2
$a výsledek terapie $7 D016896
650    _2
$a tumor burden $7 D047368
650    _2
$a ubikvitinligasy $x analýza $x genetika $7 D044767
655    _2
$a časopisecké články $7 D016428
700    1_
$a Michal, Michael $u Department of Pathology, Charles University, Biomedical Center, Faculty of Medicine in Plzen and Charles University Hospital Plzen, 304 60 Plzen, Czech Republic.
700    1_
$a Giedl, Johannes $u Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital, 91054 Erlangen, Germany.
700    1_
$a Hadravsky, Ladislav $u Department of Pathology, Charles University, Faculty of Medicine, 304 60 Plzen, Czech Republic; Department of Pathology, Charles University, 3rd Medical Faculty and Charles University Hospital Royal Vineyards, 100 00 Prague, Czech Republic.
700    1_
$a Michal, Michal $u Department of Pathology, Charles University, Faculty of Medicine, 304 60 Plzen, Czech Republic.
773    0_
$w MED00002080 $t Human pathology $x 1532-8392 $g Roč. 60, č. - (2017), s. 192-198
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27825811 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025123022 $b ABA008
999    __
$a ok $b bmc $g 1254896 $s 992330
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 60 $c - $d 192-198 $e 20161104 $i 1532-8392 $m Human pathology $n Hum Pathol $x MED00002080
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...